Full-stack drug discovery company for inherited metabolic diseases using a yeast-avatar, patient-partnered approach.
Perlara is a drug discovery and development company focused on inherited metabolic diseases (IMDs) including congenital disorders of glycosylation, mitochondrial disorders, GPI-anchor defects, and tRNA-synthetase syndromes. Their REMIT engine builds yeast-based patient avatars, screens standardized compound libraries, validates in patient cells, and advances programs through IND-enabling studies and trials. Programs are anchored to specific patient families or foundations using an N-of-1 to larger trial model. Perlara is a product of Perlara.